"A new study on stem cell research is mind-boggling," notes emerging growth expert Toby Smith in support of his recommendation for Geron Corp. (NASDAQ: GERN).

The growth stock expert and editor of ChangeWave Investing explains, "Geron reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction.

"Published online on Aug. 26, in Nature Biotechnology, the landmark study is the first to document the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the site of the infarct.

"In addition, the research confirms the effectiveness of a scalable production system that enables Geron to manufacture the cardiomyocytes for use in ongoing large animal studies and, ultimately, testing in humans."

Continue reading Geron (GERN): 'Mind-boggling' study boost stem cell research firm

Geron (GERN): 'Mind-boggling' study boost stem cell research firm originally appeared on BloggingStocks on Mon, 17 Sep 2007 08:30:00 EST. Please see our terms for use of feeds.